192 related articles for article (PubMed ID: 35744918)
1. Irreversible Antagonists for the Adenosine A
Temirak A; Schlegel JG; Voss JH; Vaaßen VJ; Vielmuth C; Claff T; Müller CE
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744918
[TBL] [Abstract][Full Text] [Related]
2. A
Jiang J; Seel CJ; Temirak A; Namasivayam V; Arridu A; Schabikowski J; Baqi Y; Hinz S; Hockemeyer J; Müller CE
J Med Chem; 2019 Apr; 62(8):4032-4055. PubMed ID: 30835463
[TBL] [Abstract][Full Text] [Related]
3. A
Tay AHM; Prieto-Díaz R; Neo S; Tong L; Chen X; Carannante V; Önfelt B; Hartman J; Haglund F; Majellaro M; Azuaje J; Garcia-Mera X; Brea JM; Loza MI; Jespers W; Gutierrez-de-Teran H; Sotelo E; Lundqvist A
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580926
[TBL] [Abstract][Full Text] [Related]
4. 1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.
Hayallah AM; Sandoval-Ramírez J; Reith U; Schobert U; Preiss B; Schumacher B; Daly JW; Müller CE
J Med Chem; 2002 Mar; 45(7):1500-10. PubMed ID: 11906291
[TBL] [Abstract][Full Text] [Related]
5. Exploring Biginelli-based scaffolds as A
Prieto-Díaz R; Fojo-Carballo H; Majellaro M; Tandarić T; Azuaje J; Brea J; Loza MI; Barbazán J; Salort G; Chotalia M; Rodríguez-Pampín I; Mallo-Abreu A; Rita Paleo M; García-Mera X; Ciruela F; Gutiérrez-de-Terán H; Sotelo E
Biomed Pharmacother; 2024 Apr; 173():116345. PubMed ID: 38442670
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of novel xanthine derivatives as potent and selective A
Basu S; Barawkar DA; Ramdas V; Patel M; Waman Y; Panmand A; Kumar S; Thorat S; Naykodi M; Goswami A; Reddy BS; Prasad V; Chaturvedi S; Quraishi A; Menon S; Paliwal S; Kulkarni A; Karande V; Ghosh I; Mustafa S; De S; Jain V; Banerjee ER; Rouduri SR; Palle VP; Chugh A; Mookhtiar KA
Eur J Med Chem; 2017 Jul; 134():218-229. PubMed ID: 28415011
[TBL] [Abstract][Full Text] [Related]
7. Fluorescent-Labeled Selective Adenosine A
Köse M; Gollos S; Karcz T; Fiene A; Heisig F; Behrenswerth A; Kieć-Kononowicz K; Namasivayam V; Müller CE
J Med Chem; 2018 May; 61(10):4301-4316. PubMed ID: 29681156
[TBL] [Abstract][Full Text] [Related]
8. Development of subtype-selective covalent ligands for the adenosine A
Beerkens BLH; Wang X; Avgeropoulou M; Adistia LN; van Veldhoven JPD; Jespers W; Liu R; Heitman LH; IJzerman AP; van der Es D
RSC Med Chem; 2022 Jul; 13(7):850-856. PubMed ID: 35923720
[TBL] [Abstract][Full Text] [Related]
9. Kinetic profiling and functional characterization of 8-phenylxanthine derivatives as A
Vlachodimou A; de Vries H; Pasoli M; Goudswaard M; Kim SA; Kim YC; Scortichini M; Marshall M; Linden J; Heitman LH; Jacobson KA; IJzerman AP
Biochem Pharmacol; 2022 Jun; 200():115027. PubMed ID: 35395239
[TBL] [Abstract][Full Text] [Related]
10. Tritium-labeled agonists as tools for studying adenosine A
Hinz S; Alnouri WM; Pleiss U; Müller CE
Purinergic Signal; 2018 Sep; 14(3):223-233. PubMed ID: 29752618
[TBL] [Abstract][Full Text] [Related]
11. The hybrid molecule, VCP746, is a potent adenosine A2B receptor agonist that stimulates anti-fibrotic signalling.
Vecchio EA; Chuo CH; Baltos JA; Ford L; Scammells PJ; Wang BH; Christopoulos A; White PJ; May LT
Biochem Pharmacol; 2016 Oct; 117():46-56. PubMed ID: 27520486
[TBL] [Abstract][Full Text] [Related]
12. Exploring the Effect of Halogenation in a Series of Potent and Selective A
Prieto-Díaz R; González-Gómez M; Fojo-Carballo H; Azuaje J; El Maatougui A; Majellaro M; Loza MI; Brea J; Fernández-Dueñas V; Paleo MR; Díaz-Holguín A; Garcia-Pinel B; Mallo-Abreu A; Estévez JC; Andújar-Arias A; García-Mera X; Gomez-Tourino I; Ciruela F; Salas CO; Gutiérrez-de-Terán H; Sotelo E
J Med Chem; 2023 Jan; 66(1):890-912. PubMed ID: 36517209
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of endogenous A
Goulding J; May LT; Hill SJ
Biochem Pharmacol; 2018 Jan; 147():55-66. PubMed ID: 29106905
[TBL] [Abstract][Full Text] [Related]
14. Ligand-Independent Adenosine A2B Receptor Constitutive Activity as a Promoter of Prostate Cancer Cell Proliferation.
Vecchio EA; Tan CY; Gregory KJ; Christopoulos A; White PJ; May LT
J Pharmacol Exp Ther; 2016 Apr; 357(1):36-44. PubMed ID: 26791603
[TBL] [Abstract][Full Text] [Related]
15. Capadenoson, a clinically trialed partial adenosine A
Baltos JA; Vecchio EA; Harris MA; Qin CX; Ritchie RH; Christopoulos A; White PJ; May LT
Biochem Pharmacol; 2017 Jul; 135():79-89. PubMed ID: 28344125
[TBL] [Abstract][Full Text] [Related]
16. 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity.
Borrmann T; Hinz S; Bertarelli DC; Li W; Florin NC; Scheiff AB; Müller CE
J Med Chem; 2009 Jul; 52(13):3994-4006. PubMed ID: 19569717
[TBL] [Abstract][Full Text] [Related]
17. A
Gao ZG; Jacobson KA
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627281
[TBL] [Abstract][Full Text] [Related]
18. A
De Filippo E; Hinz S; Pellizzari V; Deganutti G; El-Tayeb A; Navarro G; Franco R; Moro S; Schiedel AC; Müller CE
Biochem Pharmacol; 2020 Feb; 172():113718. PubMed ID: 31751537
[TBL] [Abstract][Full Text] [Related]
19. Exploring the structural determinants of novel xanthine derivatives as A
Yang Y; Li Y; Zhou W; Chen Y; Wu Q; Pan Y; Zhang S; Yang L
J Biomol Struct Dyn; 2019 Aug; 37(13):3467-3481. PubMed ID: 30175951
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.
Baraldi PG; Tabrizi MA; Preti D; Bovero A; Romagnoli R; Fruttarolo F; Zaid NA; Moorman AR; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 2004 Mar; 47(6):1434-47. PubMed ID: 14998332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
